Bevacizumab for advanced breast cancer. Review uri icon

Overview

abstract

  • Tumor angiogenesis is essential for the growth and metastasis of solid tumors. In breast cancer, increased levels of vascular endothelial growth factor (VEGF) have been associated with poor prognosis in lymph node-positive and lymph node-negative patients. In addition to its prognostic significance, VEGF is now a validated target in the treatment of breast cancer. Bevacizumab, an anti-VEGF antibody, has demonstrated significant clinical benefit in several solid tumors. In this article the authors discuss the data pertaining to bevacizumab and other antiangiogenic agents for the treatment of patients who have advanced breast cancer.

publication date

  • April 1, 2007

Research

keywords

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Breast Neoplasms
  • Neovascularization, Pathologic

Identity

Scopus Document Identifier

  • 34248576452

Digital Object Identifier (DOI)

  • 10.1016/j.hoc.2007.03.006

PubMed ID

  • 17512451

Additional Document Info

volume

  • 21

issue

  • 2